Key Points
- Director George Pavlov purchased a total of 25,000 shares of Maplight Therapeutics across Feb 18–20 at average prices around $17.48–$17.86, spending roughly $441,168; after the Feb 19 filing his direct stake was reported as 15,080 shares, a 41.49% increase.
- Maplight is a clinical-stage biotech trading near $17.88 with a market cap of about $811 million and a negative P/E; the company reported a huge quarterly EPS miss ($(37.18) vs. $(1.86) estimate) while analysts show a “Moderate Buy” consensus with an average target of $31.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director George Pavlov bought 4,422 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The shares were purchased at an average cost of $17.57 per share, with a total value of $77,694.54. Following the purchase, the director directly owned 15,080 shares of the company's stock, valued at approximately $264,955.60. This represents a 41.49% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
George Pavlov also recently made the following trade(s):
- On Friday, February 20th, George Pavlov purchased 9,920 shares of Maplight Therapeutics stock. The stock was acquired at an average price of $17.86 per share, for a total transaction of $177,171.20.
- On Wednesday, February 18th, George Pavlov acquired 10,658 shares of Maplight Therapeutics stock. The shares were acquired at an average price of $17.48 per share, with a total value of $186,301.84.
Maplight Therapeutics Price Performance
NASDAQ MPLT opened at $17.88 on Friday. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $21.55. The company has a market cap of $811.22 million and a P/E ratio of -0.48. The stock has a 50 day simple moving average of $17.93.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing analysts' consensus estimates of ($1.86) by ($35.32).
Wall Street Analysts Forecast Growth
MPLT has been the topic of a number of recent analyst reports. Stifel Nicolaus began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a "buy" rating and a $28.00 target price on the stock. Zacks Research raised Maplight Therapeutics to a "hold" rating in a research note on Monday, November 24th. Weiss Ratings began coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a "sell (e)" rating for the company. Leerink Partners assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an "outperform" rating and a $30.00 price target for the company. Finally, Wall Street Zen upgraded shares of Maplight Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.00.
Read Our Latest Stock Report on Maplight Therapeutics
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of MPLT. Strs Ohio acquired a new position in Maplight Therapeutics in the 4th quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics in the fourth quarter worth approximately $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics in the fourth quarter valued at approximately $205,000.
Maplight Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
